4 tips for biomedical startups looking to partner with big pharma
Mon, 04/29/2024 - 12:00
Partnering bigger industry players and investors is critical for smaller startups to achieve scale and success. But how do they secure such collaboration or funding? Panellists at a discussion by SGInnovate and the Biomedical Sciences Industry Partnership Office show the way forward.
Network with and hear from industry experts at upcoming community events here.
The feelings are mutual – While startups are eyeing tie-ups with big industry players, global pharmaceutical companies are also keen to partner startups for the next big discovery.
“There’s a reason why we’ve outsourced innovation, because biotech startups and universities are better equipped to drive our discoveries,” said Ms Miemie Strydom, Director of New Business Development at Johnson & Johnson Innovative Medicine.
She was speaking at a panel discussion, Evaluating Science through the Lens of Commercialisation, organised by the Agency for Science, Technology and Research’s (A*STAR) academic-industry research partnerships office, Biomedical Sciences Industry Partnership Office (BMSIPO), and SGInnovate. She disclosed that more than 50 per cent of her company’s revenue is driven by the results of such partnerships.